Inpharma Weekly

, Volume 965, Issue 1, pp 4–6 | Cite as


the first study to show that cholesterol reduction saves lives
  • Gill Higgins
Newsletter Article


For the first time, the ability of simvastatin to ‘ save lives ’ has been shown in a large, placebo-controlled trial involving patients with coronary artery disease. This is good news for Merck, as the results are likely to give physicians renewed confidence in prescribing simvastatin to patients with this condition. Although simvastatin stole the show at the 67th Scientific Sessions of the American Heart Association [ Dallas, US; November 1994 ], ground-breaking results were also presented for pravastatin. The Kuopio Atherosclerosis Prevention Study (KAPS) showed that this drug is effective in the primary prevention setting. Compared with placebo, pravastatin significantly reduced the risk of atherosclerosis in individuals with mild to moderate hypercholesterolaemia who had no cardiac disease.


Simvastatin Coronary Artery Bypass Graft Pravastatin Fluvastatin Total Cholesterol Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Adis International Ltd 1994

Authors and Affiliations

  • Gill Higgins

There are no affiliations available

Personalised recommendations